GIST

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses results of the CanStem111P trial, a phase III study of napabucasin plus nab-paclitaxel with gemcitabine in adult patients with metastatic pancreatic adenocarcinoma.

Drug manufacturer XBiotech has cancelled the phase III XCITE study of MABp1 (Hutruo; formerly Xilonix) in patients with advanced colorectal cancer, following a second prospectively planned, unblinded analysis.

Unresectable Metastatic Gastrointestinal Stromal Tumor

Unresectable Metastatic Gastrointestinal Stromal Tumor

Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses efficacy and safety results for pembrolizumab (Keytruda) monotherapy in patients with previously treated advanced gastric cancer.

Brian Wolpin, MD, MPH, has been named director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute.

Nivolumab (Opdivo) has been granted a priority review designation by the FDA for use as a treatment for patients with hepatocellular carcinoma following prior sorafenib (Nexavar).

Pembrolizumab (Keytruda) has been granted a priority review by the FDA for the treatment of patients who have undergone at least 2 courses of chemotherapy for recurrent or advanced gastric or gastroesophageal junction adenocarcinoma.

Pembrolizumab (Keytruda) has been granted an accelerated approval by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors.

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses a study exploring the molecular variances between rectal and left-sided colon cancers.

Results from a recent study showed patients with stage III colorectal cancer experienced a 42% lower chance of death and a trend toward reduced cancer recurrence if they maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors.

Eating tree nuts, like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer, findings of a new prospective study suggest.

Overall survival was improved by 15 months for patients with macroscopically resected biliary tract cancer who were treated with adjuvant capecitabine compared with observation alone.

John Marshall, MD, of Georgetown Lombardi and MedStar Georgetown University Hospital, has been appointed chief medical officer of Caris Life Sciences.

Current guidelines recommend waiting 6 months before resecting a large hepatocellular adenoma to prevent a transformation to a malignant tumor; however, a recent study suggests that waiting longer could benefit some patients.

Tim F. Greten, MD, discusses the evolving role of immunotherapy in HCC.

Fahima Dossa, MD, and Nancy Baxter, MD, PhD, discuss the potential of using a watch-and-wait approach in the management of patients with rectal cancer.

Jonathan Strosberg, MD, discusses recent developments and emerging agents in the field of NETs.

Researchers at Vanderbilt University and the University of Leeds in England have successfully performed autonomous retroflexion of a robotic capsule during colonoscopy in a subject animal.

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses findings of how early-onset colorectal cancer is distinct from traditional colorectal cancer.